1. Home
  2. DMAC vs ALT Comparison

DMAC vs ALT Comparison

Compare DMAC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • ALT
  • Stock Information
  • Founded
  • DMAC 2000
  • ALT 1997
  • Country
  • DMAC United States
  • ALT United States
  • Employees
  • DMAC N/A
  • ALT N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • DMAC Health Care
  • ALT Health Care
  • Exchange
  • DMAC Nasdaq
  • ALT Nasdaq
  • Market Cap
  • DMAC 310.1M
  • ALT 292.0M
  • IPO Year
  • DMAC N/A
  • ALT N/A
  • Fundamental
  • Price
  • DMAC $5.98
  • ALT $3.67
  • Analyst Decision
  • DMAC Strong Buy
  • ALT Strong Buy
  • Analyst Count
  • DMAC 3
  • ALT 6
  • Target Price
  • DMAC $12.33
  • ALT $17.40
  • AVG Volume (30 Days)
  • DMAC 314.0K
  • ALT 2.8M
  • Earning Date
  • DMAC 08-12-2025
  • ALT 08-12-2025
  • Dividend Yield
  • DMAC N/A
  • ALT N/A
  • EPS Growth
  • DMAC N/A
  • ALT N/A
  • EPS
  • DMAC N/A
  • ALT N/A
  • Revenue
  • DMAC N/A
  • ALT $20,000.00
  • Revenue This Year
  • DMAC N/A
  • ALT N/A
  • Revenue Next Year
  • DMAC N/A
  • ALT $761,880.20
  • P/E Ratio
  • DMAC N/A
  • ALT N/A
  • Revenue Growth
  • DMAC N/A
  • ALT N/A
  • 52 Week Low
  • DMAC $3.19
  • ALT $2.90
  • 52 Week High
  • DMAC $6.82
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 65.09
  • ALT 46.45
  • Support Level
  • DMAC $5.90
  • ALT $3.35
  • Resistance Level
  • DMAC $6.18
  • ALT $3.66
  • Average True Range (ATR)
  • DMAC 0.39
  • ALT 0.18
  • MACD
  • DMAC 0.02
  • ALT 0.05
  • Stochastic Oscillator
  • DMAC 79.10
  • ALT 58.57

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: